leprosy
Conditions
Interventions
Group 1:A single dose of rifampicin
Group 2:A single dose of rifapentine
Group 3:no chemoprophylaxis intervention
Sponsors
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science, Peking Union Medical College
Eligibility
Sex/Gender
All
Age
10 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Definitely HHCs; 2.Aged 10-65 years; 3.Participants have no plan to permanently move away from the current trial site; 4.The researchers believe that the overall condition of the subjects does not affect the evaluation; 5.Participants are eligible and sign the informed consent.
Exclusion criteria
Exclusion criteria: 1.Cured leprosy patient; 2.Pregnant or lactating; 3.Prepare for pregnancy in the next 3 months; 4.Allergy to rifampicin or rifapentine; 5.HHC of index cases with confirmed resistance to rifampicin; 6.Participants have taken rifampicin or rifapentine in the past 3 months; 7.Currently require rifampicin for tubercular infection; 8.Concurrent conditions (neurological and psychiatric disorders, severe or aggravating hematonosis, heart diseases, severely abnormal liver and kidney function or peptic ulcer); 9.Other contraindicating conditions.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The cumulative incidence rate of leprosy in HHCs over the 4-year follow-up period; | — |
Secondary
| Measure | Time frame |
|---|---|
| Safety evaluation at 2 weeks after the intervention;The cumulative incidence rate of leprosy in HHCs over the 2-year follow-up period.;Subgroup analysis over the 4-year follow-up period.;The cost-effectiveness evaluation over the 4-year follow-up period.; | — |
Countries
China
Contacts
Public ContactWang Baoxi
Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Science, Peking Union Medical College
Outcome results
None listed